Strategic partnerships with CROs key to patient recruitment

By Nick Taylor

- Last updated on GMT

Related tags Patient recruitment Patient Contract research organization

Forming a strategic partnership with a CRO is one of the key steps to boosting patient recruitment, according to a report.

Close collaboration between a contract research organisation (CRO) and sponsor makes both firms aware of the others’ needs and limitations. This helps the sponsor select the CRO which can best meet its recruitment needs for specific phases, therapeutic areas or geographies.

Business intelligence firm Cutting Edge Information (CEI) reached this conclusion after surveying 84 companies and interviewing seven of these firms. In the resulting report it details best practices for increasing patient recruitment rates, including how and why to work with CROs.

Outsourcing allows firms to benefit from the dedicated patient recruitment groups and databases with site-specific demographic information possessed by many CROs. Using these tools CROs can determine the likelihood of seeing strong recruitment at each site for any trial type.

Maximising benefits

To maximise the advantages of working with CROs CEI recommends entering into strategic partnerships. CEI notes that the prospect of repeat business means CROs will strive to provide the best service to strategic partners, even making short-term sacrifices for the sponsor’s benefit.

When selecting a vendor CEI recommends firms follow certain principles. Master agreements should be used to reduce contract negotiation time and give the flexibility to speed up the process for a certain trial.

Collaborating gives a sponsor insight into the capabilities at different CROs. By understanding CROs expertise in specific trial phases, therapeutic areas, geographies and age ranges a sponsor can quickly select the most appropriate partner for a trial.

This process also gives the CRO an understanding of the sponsor’s needs. Using this experience the CRO can make informed decisions when selecting trials, which is particularly important if the sponsor fails to provide key information, such as per patient reimbursement or final trial protocol.

CROs may also have long-term relationships with sites and physicians. If the CRO knows the sponsor’s clinical pipeline for the coming year, and the capabilities of its partner sites, it can quickly determine which location is suitable for which developmental product.

A collaboration case study

The report cites the example of Company A, a large CRO at which a patient recruitment executive operates under the RACI (responsible, accountable, consult, inform) system.

At Company A one group is focused on recruitment and has ultimate responsibility for this task. However, this group collaborates closely with the sponsor’s project managers, clinical operations team, physicians on the study, medics, marketing department, and other units at the CRO.

This cross-functional input ensures that the patient recruitment efforts incorporated into the trial protocol have been informed by knowledge companywide and that everyone is aware of the recruitment strategy​”, wrote CEI.

Adopting an approach that considers patients’ perspectives avoids three major pitfalls by ensuring: protocol wording makes it easy for patients to participate; sites with access to targeted patients are selected; and the sponsor has a communication strategy in place.

Related news

Show more

Related products

show more

Unlock potential in buffer preparation

Unlock potential in buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Sep-2023 | Infographic

Consider how the right partner can help you scale faster, mitigate risks, and optimize resources.

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 14-Aug-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

Related suppliers

Follow us


View more